.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,270,831

« Back to Dashboard

Details for Patent: 7,270,831

Title:Orally administrable opioid formulations having extended duration of effect
Abstract: Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in sustained release form. The substrates have a diameter from about 0.1 mm to about 3 mm.
Inventor(s): Oshlack; Benjamin (New York, NY), Chasin; Mark (Manalapan, NJ)
Assignee: Purdue Pharma L.P. (N/A)
Filing Date:Mar 20, 2003
Application Number:10/392,586
Claims:1. An oral analgesic dosage form for once-a-day administration, comprising (a) sustained release beads comprising sugar beads, a coating comprising morphine sulphate on the sugar beads and an overcoating comprising one or more ammonio methacrylate copolymers on the coated sugar beads; and (b) immediate release beads comprising sugar beads and a coating comprising morphine sulphate on the sugar beads; the total amount of morphine sulphate in the dosage form being about 5 mg to about 800 mg; the dosage form providing an analgesic effect for about 24 hours or more after oral administration to a human patient.

2. The dosage form of claim 1, wherein the sustained release beads and the immediate release beads are contained in a gelatin capsule.

3. The dosage form of claim 1, wherein the total amount of morphine sulphate in the dosage form is 30 mg.

4. The dosage form of claim 1, which provides effective steady-state blood plasma levels of said morphine for at least about 24 hours.

5. The dosage form of claim 1, wherein the overcoating of the controlled release beads further comprises talc.

6. The dosage form of claim 1, wherein the coating of the controlled release beads and the immediate release beads further comprises povidone.

7. A method of preparing an oral analgesic dosage form for once-a-day administration, comprising (a) preparing sustained release beads comprising coating sugar beads with a coating comprising morphine sulphate and overcoating the coated sugar beads with an overcoating comprising one or more ammonio methacrylate copolymers; and (b) preparing immediate release beads comprising coating sugar beads with a coating comprising morphine sulphate; the total amount of morphine sulphate in the dosage form being about 5 mg to about 800 mg; the dosage form providing an analgesic effect for about 24 hours or more after oral administration to a human patient.

8. The method of claim 7, further comprising containing the sustained release beads and the immediate release beads in a gelatin capsule.

9. The method of claim 7, wherein the total amount of morphine sulphate in the dosage form is 30 mg.

10. The method of claim 7, wherein the dosage form provides effective steady-state blood plasma levels of said morphine for at least about 24 hours.

11. The method of claim 7, wherein the overcoating of the controlled release beads further comprises talc.

12. The method of claim 7, wherein the coating of the controlled release beads and the immediate release beads further comprises povidone.

13. The dosage form of claim 1, wherein the total amount of morphine sulphate in the dosage form is from 5 mg to 800 mg.

14. The method of claim 7, wherein the total amount of morpine sulphate in the dosage form is from 5 mg to 800 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc